Doctors tend to focus only on those illnesses they can treat effectively
New Medications to Fight the Misery of Craving
Doctors tend to focus on those illnesses they can treat, and for the last century that
has kept addiction out of the game. Whereas most areas of medicine have dozens of effective medications at their disposal to treat their patients, addiction medicine has always been handicapped by its limited formulary. Especially distressing has been the lack of an effective drug to combat craving - a drug that could provide relief to addicted patients in early abstinence, and help them remain in treatment.
Fortunately, recent research into the neurophysiology of addiction reveals exciting
possibilities for the treatment of addiction. New anti-craving drugs are now on the market, and more in the investigational stages that could change the face of addiction treatment.
Drugs that block the effects of heroin and other narcotics, also known as "opioid
antagonists", have been around for decades but their usefulness in treating addictions has only recently been discovered. Researchers at the University of Pennsylvania found that newly abstinent alcoholics given naltrexone (ReVia, made by DuPont, and Vivitrol made by Alkermes) reported less craving for alcohol. In addition, those alcoholic patients who relapsed while taking naltrexone drank fewer days before returning to abstinence than those patients given a placebo. Why a drug that blocks opioid receptors would be effective in treating alcohol cravings remains a mystery - especially since naltrexone, while it very effectively prevents narcotic addicts from experiencing euphoria after taking opioids, does nothing to relieve craving for opioids.
What is particularly fascinating about naltrexone is that when the drug was
administered to gambling addicts, these patients reported less craving for gambling. In addition, gambling addicts who relapsed to gambling while taking naltrexone gambled less money before returning to abstinence. The possible connection between the GABA system, the neurotransmitter system affected by alcohol, and gambling behaviors is under intense investigation.
Acamprosate Another new anti-craving medication on the market is acamprosate (Campral,
made by Forest pharmaceuticals). Acamprosate has been used in Europe for many years and is proven to reduce cravings for alcohol.
No one is quite sure how acamprosate works, but some have postulated that this
drug can "bridge the gap" in the brain between the depleted GABA (inhibitory) system and the glutamate (excitatory) system that occurs in patients newly abstinent from alcohol. The evidence is increasingly clear that leaving the patient in this state of unopposed excitation is actually toxic to the brain. Acamprosate protects the brain until the GABA and glutamate systems can come back into balance, and this may dramatically increase treatment retention in the critical few months of recovery.
Corticotropin Releasing Factor- Antagonists
Probably the most exciting area of research in addiction medicine involves drugs
that block the stress reactions that trigger cravings and can lead to relapse. This research involves a particular hormone critical to the brain's stress response known as Corticotropin Releasing Factor, or CRF. It should come as no surprise that mice, first addicted to cocaine, then abstinent for several months, but then submitted to stressful experiences - either random foot shocks or forced-swimming in water - and given cocaine relapse faster than non-stressed mice. What is fascinating is that mice who are first addicted, then abstinent, and then stressed but given a drug that blocks CRF along with cocaine do not relapse. This compelling research implicates CRF as the key hormone involved in craving and relapse. Drugs that block CRF receptors could prove to be the Holy Grail of addiction medicine - a drug that stops relapse.
You might well ask, "Then where can I get that drug, Doc!?" The only difficulty
is that these CRF-antagonists also shut down the immune system, and the poor mouse dies of infection. However, as you read this I can assure you that the race is on to find the CRF-antagonist that selectively blocks craving but preserves immune function.
Soon addiction medicine, like other specialties of medicine, will have a handful of
medications all its own - a little "bag of tricks" so to speak to help patients get through their first year of sobriety. Think how much easier the practice of addiction medicine will be with these medications! I personally believe that when the word gets out that these drugs work and doctors realize something that we in the treatment field have always known - that addicts are wonderful patients and it is fun to watch them get sober - there will be increased excitement about addiction medicine. Doctors will want to become certified as addiction specialists and a renaissance in the treatment of addiction will begin!
One thing should always be kept in mind: these medications can relieve the
symptoms of craving and prevent relapse, but they do not have the power to fix the underlying spiritual malady that powers the disease of addiction in the first place. Only the program of Alcoholics Anonymous can do that. In the end there is no easier, softer way. However, these medications could aid tremendously in helping the newly sober addict keep coming back until the Twelve-steps can work their magic.
Uma guerra entre os dois países, além de massacrar, possivelmente, milhares de árabes e israelenses, bem como norte-americanos, elevaria o preço do gás e do petróleo a um nível inimaginável, catapultado para uma cifra superior a US$ 250, ou mesmo chegar US$ 500 o barril, interrompendo o comércio e causando um cataclismo na economia mundial, já abalada e deprimida, desde 2007-2008, pel
de in dieser Untersuchung EEG-Feedback mit einem computerisier-Pregabalin (300 mg/d) als Add-on Therapie untersucht. Erfasst wur-ten Aufmerksamkeitstraining im Rahmen eines multimodalen Be-den Depressivität, Angstniveau und Aggressivität, kurz- und langfris-tige Gedächtnisleistungen und Aufmerksamkeit. Prä- und Post-28 Kinder mit ADHS wurden randomisiert mit 20 Sitzungen EEG-Treatment